ANTIANGIOGENIC THERAPY APPLICABLE FOR TREATMENT OF BREAST CANCER

摘要

1. A method of treating an individual in whom a locally recurring or metastatic breast cancer has been diagnosed, wherein said method comprises administering to a specified individual a treatment regimen comprising administering an effective amount of at least one chemotherapeutic agent and an anti-VEGF antibody, wherein no individual has been administered which or a chemotherapeutic agent for the treatment of locally recurring or metastatic breast cancer, and / or said individual has not been previously th auxiliary chemotherapy in relapsed within 12 months or less after the last dose, and wherein the treatment regimen effectively contributed to increase the duration of the individual PFS disease.2. The method according to claim 1, wherein said chemotherapeutic agent is capecitabine, taxane, anthracycline, paclitaxel, docetaxel, particles associated with paclitaxel protein (e.g. Abraxane®), doxorubicin, epirubicin, 5-fluorouracil, cyclophosphamide, or combinations thereof. The method of claim 1, wherein said chemotherapy regimen comprises administering FEC: 5-fluorouracil, epirubicin and cyclophosphamide, or FAC: 5-fluorouracil, doxorubicin and cyclophosphamide, or AC: doxorubicin and cyclophosphamide, or EC: epirubicin and cyclophosphamide. The method of claim 1, wherein said anti-VEGF antibody binds to the same epitope to which anti-VEGF antibody A4.6.1 binds produced by ATCC HB 10709.5 hybridoma. The method of claim 1, wherein said anti-VEGF antibody is a humanized antibody. The method of claim 1, wherein said individual is HER2-negative. The method according to claim 1, where the decree